IDWeek 2022

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

Michael D. Huband
Associate Director
345 Beaver Kreek Center
North Liberty, IA 52317
319-665-3370
michael-huband@jmilabs.com

Table 2. Antimicrobial activity of omadacycline and tetracycline comparators against bacterial isolates collected from patients with community-acquired respiratory tract infections in United States medical centers (2020–2021)